FY2026 EPS Estimates for MeiraGTx Boosted by HC Wainwright

MeiraGTx Holdings PLC (NASDAQ:MGTX) – Stock analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of MeiraGTx in a note issued to investors on Thursday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn $0.36 per share for the year, up from their previous forecast of ($1.89). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for MeiraGTx’s Q4 2026 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.48) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($1.45) EPS.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings data on Thursday, August 13th. The company reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $2.17. The firm had revenue of $321.43 million during the quarter, compared to the consensus estimate of $0.70 million. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%.

MGTX has been the subject of a number of other reports. Royal Bank Of Canada lifted their price target on shares of MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of MeiraGTx in a report on Friday, July 17th. Zacks Research raised shares of MeiraGTx from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 13th. Piper Sandler lifted their target price on shares of MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a report on Wednesday, April 22nd. Finally, Wall Street Zen raised MeiraGTx from a “hold” rating to a “buy” rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $26.17.

MeiraGTx Trading Up 1.8%

NASDAQ MGTX opened at $13.77 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.76 and a quick ratio of 3.76. The stock has a market capitalization of $1.28 billion, a P/E ratio of 19.39 and a beta of 1.23. The firm’s 50-day moving average is $12.18 and its two-hundred day moving average is $9.87. MeiraGTx has a 12 month low of $6.62 and a 12 month high of $15.35.

Insider Activity

In other news, CFO Richard Giroux sold 56,000 shares of the stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $12.51, for a total transaction of $700,560.00. Following the sale, the chief financial officer owned 908,530 shares of the company’s stock, valued at approximately $11,365,710.30. This represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $14.80, for a total transaction of $409,353.20. Following the completion of the transaction, the insider directly owned 640,846 shares of the company’s stock, valued at approximately $9,484,520.80. The trade was a 4.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC increased its stake in MeiraGTx by 0.4% during the 2nd quarter. Perceptive Advisors LLC now owns 12,626,103 shares of the company’s stock worth $82,231,000 after buying an additional 45,000 shares during the period. Rubric Capital Management LP boosted its position in MeiraGTx by 13.4% in the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock valued at $60,620,000 after buying an additional 824,669 shares during the period. Johnson & Johnson purchased a new position in MeiraGTx in the 2nd quarter valued at approximately $89,720,775,000. Adage Capital Partners GP L.L.C. grew its stake in shares of MeiraGTx by 7.1% in the second quarter. Adage Capital Partners GP L.L.C. now owns 6,034,578 shares of the company’s stock worth $39,345,000 after acquiring an additional 400,000 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in shares of MeiraGTx in the second quarter worth $64,269,000. Institutional investors and hedge funds own 67.48% of the company’s stock.

MeiraGTx Company Profile

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.